ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.
FDA Rejects Nasal Spray For Severe Allergic Reactions—Delaying First Needle-Free EpiPen Alternative
ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.